FOLIA BIOTECH

FOLIA BIOTECH is a clinical stage biopharmaceutical company focused on exploiting its proprietary immuno-therapeutic platform to bring to market highly efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases.

Folia's immuno-therapeutic platform consists of a novel Toll-Like Receptor (TLR7) agonist nanoparticle.

The company was founded in 2006 by Dr. Denis Leclerc, a researcher at the Centre Hospitalier Universitaire de Québec (CHU de Québec). The technology emerged from the Infectious Disease Research Center (CRI) of Laval University.

STRATEGY

  • Exploit the immunomodulatory properties of FOLIA's technology for immuno-oncology and immune diseases
  • Create strategic partnerships to exploit the technology's full commercial potential
  • Develop innovative vaccines based on our immuno-therapeutic platform

MANAGEMENT TEAM

FOLIA BIOTECH relies on the complementarity of expertise, experience and knowledge of its management team to propel its technological innovations to the highest peaks and to insure the success of the company and its products.

 

MANAGEMENT TEAM

Photo M. Louis R. Lamontagne

Louis R. Lamontagne, Ph. D.,

President and Chief Executive Officer

Dr. Lamontagne serves as CEO of FOLIA BIOTECH since 2014. His impressive career is distinguished by its 25 years of experience in the management of biopharmaceutical organizations and companies such as Neurochem and PainCeptor. More specifically, Dr. Lamontagne has completed several private and public financings (IPO), and realized important partnerships and strategic alliances for the development of many organizations.

Mr. Lamontagne holds a BA in Chemistry from Queen's University, a PhD in Immunology from McMaster University, and did post-graduate studies in Tropical Public Health at Harvard University.

 

MANAGEMENT TEAM

Photo M. Denis Leclerc

Denis Leclerc, Ph. D.,

Vice President and Chief Scientific Officer

Dr. Leclerc is the founder of FOLIA BIOTECH and currently holds the position of Vice President and Chief Scientific Officer. Dr. Leclerc is a professor at Laval University Faculty of Medicine and researcher at the Infectious Disease Research Center (CRI) of the CHU de Québec.

He holds a PhD in Virology from University of Toronto and conducted postdoctoral studies at the Friedrich Miescher Institute for Biomedical Research in Switzerland. His research activities focus mainly on the development of new adjuvants and more effective vaccines. He is author or co-author of 59 scientific articles in the field of virology, immunology and vaccination. He is the principal inventor of 8 patents covering all aspects of FOLIA BIOTECH products portfolio.

 

MANAGEMENT TEAM

Photo M. Pierre Savard

Pierre Savard, Ph. D.,

Regulatory Affairs and Manufacturing

Dr. Savard joined FOLIA BIOTECH in 2008, and he oversees regulatory affairs and manufacturing. Dr. Savard is a professor at Laval University Faculty of Medicine and researcher at the neuroscience axis of the Research Centre of the CHU de Québec.

He holds a PhD in Physiology from Laval University, and also pursued postdoctoral studies in Retrovirology at the Institut de recherches cliniques de Montréal and in Developmental Biology at the Ludwig Institute for Cancer Research in London.

 

BOARD OF DIRECTORS

FOLIA BIOTECH benefits greatly from the guidance and the active participation of members of the Board of Directors in developing and pursuing its strategic orientation.

 

BOARD OF DIRECTORS

Pierre Falardeau, Ph. D.,

Chairman of the Board

Dr. Falardeau was elected Chairman of the Board of FOLIA BIOTECH in 2014. He accumulated extensive experience in drug development during his many years working in the fields of oncology and product development. From 1998 to 2002, Dr. Falardeau has been very active at Æterna-Zentaris, first as director of scientific affairs and then as Vice President of Scientific Affairs. From 2002 to 2007 he was President and CEO of Ecopia Biosciences inc. Since January 2010, he is President and CEO of Oncozyme Pharma (now Verlyx Pharma Inc.) and is also the founder and President of the consulting company Pharm-Asset Inc.

He holds a PhD in Pharmacology and physiology from Laval University in Quebec and pursued postdoctoral studies at the Howard Hughes Medical Institute at Duke University, in Durham, North Carolina.

 

BOARD OF DIRECTORS

Denis Leclerc, Ph. D.,

Vice President and Chief Scientific Officer

Dr. Leclerc is the founder of FOLIA BIOTECH and currently holds the position of Vice President and Chief Scientific Officer. Dr. Leclerc is a professor at Laval University Faculty of Medicine and researcher at the Infectious Disease Research Center (CRI) of the CHU de Québec.

He holds a PhD in Virology from University of Toronto and conducted postdoctoral studies at the Friedrich Miescher Institute for Biomedical Research in Switzerland. His research activities focus mainly on the development of new adjuvants and more effective vaccines. He is author or co-author of 59 scientific articles in the field of virology, immunology and vaccination. He is the principal inventor of 8 patents covering all aspects of FOLIA BIOTECH products portfolio.

 

BOARD OF DIRECTORS

Patrice Allibert, Ph. D.,

Director

Dr. Allibert has over 25 years of experience in the pharmaceutical and biotechnology industry. Between 1998 and 2001 he was consultant at the European Economic Community for the evaluation of programs related to genomics and proteomics. From 2001 to 2006, Dr. Allibert has conducted R&D teams in France and the United States at Merial, as director of bioanalytical development. From 2006 to 2012 he was Vice President R&D and Vice President of Molecular Innovation at BD Diagnostic GeneOhm, where he developed many products. He joined GenePOC in June 2012 as CEO.

Dr. Allibert holds a PhD in Molecular Biology from University of Grenoble in France. He is now a member of the Board of Directors of the Institute of Infection and Immunity of Canadian Institutes of Health Research (CIHR).

 

BOARD OF DIRECTORS

Jacques Bernier, B.Pharm, MBA,

Director

Mr. Bernier has been part of FOLIA's team from its inception, and acted as its CEO from 2008 to 2014. Mr. Bernier was very successful in raising private and non-dilutive investments for Folia, while navigating in a challenging financial market environment. He has developed several business partnerships and agreements that have generated business opportunities and strengthened the development of FOLIA's technology. Before his brilliant years as CEO, M. Bernier acquired a broad management experience as the owner of a group of pharmacies and on the board of directors of various pharmaceutical companies. He has a profound understanding of the pharmaceutical industry and an acute experience in business development, market analysis and negotiation of product agreement.

Mr. Bernier holds a Bachelor degree in pharmacy from Laval University. He also completed a MBA with a concentration in pharmaceutical management and a graduated program in pharmaceutical product development at Laval University.

 

BOARD OF DIRECTORS

Peter Morand, Ph. D.,

Director

Emblem and pioneer in the sector of scientific research in Canada and beyond its borders, Dr. Morand held among others, during his impressive career, the following positions: Dean of the Faculty of Science and Engineering at the University of Ottawa, President of the Natural Sciences and Engineering Research Council of Canada (NSERC) and President and CEO of the Canadian Science and Technology Growth Fund (CSTGF). He acts as member of the Board of Directors or the scientific committee of several organizations dedicated to research across Canada.

He is one of the four Canadians that have been named Knight of the National Order of Merit by the President of the French Republic in 1997 and recipient of the Commemorative Medal for the 125th Anniversary of Canada (1992). He is author or co-author of over 80 scientific publications and holds twenty patents in several countries.

Dr. Morand holds a PhD in Organic Chemistry from McGill University and pursued postdoctoral studies at the Imperial College of London.

 

BOARD OF DIRECTORS

Louis Lamontagne, Ph. D.,

Director

Dr. Lamontagne serves as CEO of FOLIA BIOTECH since 2014, and is a member of the Board since 2016. His impressive career is distinguished by its 25 years of experience in the management of biopharmaceutical organizations and companies such as Neurochem and PainCeptor. More specifically, Dr. Lamontagne has completed several private and public financings (IPO), and realized important partnerships and strategic alliances for the development of many organizations.

Mr. Lamontagne holds a BA in Chemistry from Queen's University, a PhD in Immunology from McMaster University, and did post-graduate studies in Tropical Public Health at Harvard University.

 

BOARD OF DIRECTORS

Me Charles Denault

Secretary and Legal Adviser

Mr. Denault is acting as legal advisor for FOLIA BIOTECH and he held various positions as a director or member of advisory boards in many companies. The majority of his practice is devoted to commercial law and planning. He was involved in the realization of many complex commercial transactions. Beyond the legal aspects, Mr. Denault is often involved in the trading strategy before the completion of transaction or business startups. His practice is concentrated in corporate and business law, commercial lease, shareholder or company agreements, trade financing, sales of businesses, and tax systems.

Mr. Denault holds a degree in law from University of Sherbrooke and from the Bar of Quebec, and has also a degree in notarial law.

 

SCIENTIFIC ADVISORY BOARD

FOLIA BIOTECH is proud to work with influential individuals who have gained significant credibility in North America in their respective field of expertise.

  • Scott Halperin, MD, Professor of Pediatrics, Microbiology and Immunology at Dalhousie University and head of the division of infectious diseases at the IWK health center in Halifax
  • James Richards, Ph. D., Director R&D at the National Research Council of Canada's Human Health Therapeutics, portfolio-Ottawa, and Director of the NRC vaccine program
  • Francisco Diaz-Mitoma, Ph. D., Founder, CEO and CSO of the Advanced Medical Research Institute of Canada (AMRIC), founder of the Vaccine and infectious disease research institute center at CHEO in Ottawa, founder and former CEO of Variation Biotechnologies (VBI) inc.
  • Urszula Krzych, Ph. D., Chief of the Malaria Vaccine Branch of the Department of Cellular Immunology at the Walter Reed Army Institute of Research (US Army)

 

SCIENCE AND TECHNOLOGY

FOLIA BIOTECH's technology is a potent TLR7 agonist which can be used as an immunomodulating agent or as a vaccine platform.

This technology is a promising candidate for immuno-oncology and for the treatment of immune diseases due to its ability to stimulate the innate immune system. It also offers great versatility, as it can be added to or fused with antigens of interest in vaccination to increase their immunogenicity.

FOLIA's technology is a nanoparticle derived from the nucleocapsid of Papaya mosaic virus (PapMV) that can activate endosomal immune receptors and elicit an immune response

Mechanism of action
Illustration

PRODUCT DEVELOPMENT

FOLIA BIOTECH research and development relies on scientific excellence for discovering and developing new treatments for cancer and immunes diseases as well as innovative vaccines based on our proprietary technology.

Illustration product development

PARTNERSHIPS

FOLIA BIOTECH focuses on the stages of research and the early phases of clinical development of its products. In order to accelerate their development and maximize the value of its immuno-therapeutic platform, the conclusion of corporate or academic partnerships is a key element to our business strategy.

  • Canadian Center for Vaccinology
  • Centre de recherche en infectiologie - Infectious disease research center
  • Therapure biopharma inc.
  • Prevent - Accelerating Canadian vaccine development

YOU WANT TO BECOME A PARTNER ?

CONTACT

FOLIA BIOTECH
2750, Einstein Street, suite 330
Quebec (Quebec) G1P 4R1
Canada

418 263-5180
info@foliabiotech.com

Carte
Thank you, your resquest has been submitted
All fields must be completed. Your request has not been submitted.

Information request

 
Retour haut de la page